News
Moderna (NASDAQ:MRNA) has cancelled plans to build a messenger RNA manufacturing plant in Japan, citing concerns over the ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S.
Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease ...
StockStory.org on MSN4d
Why Moderna (MRNA) Stock Is Falling TodayWhat Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results